Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients

Ph-negative chronic myeloproliferative disorders (PhnegcMPD) are treated according to the estimated vascular risk. The recent discovery of V617F point mutation of the JAK2 kinase, which frequently occurs in these diseases, has not changed their management so far. However, emerging data tend to suppo...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2009-07, Vol.88 (7), p.629-632
Main Authors: Spanoudakis, Emmanouil, Bazdiara, Ioanna, Kotsianidis, Ioannis, Margaritis, Dimitrios, Goutzouvelidis, Aggelos, Christoforidou, Anna, Tsatalas, Costas, Bourikas, George
Format: Article
Language:English
Subjects:
Bone Marrow
Clone Cells - drug effects
Clone Cells - pathology
Hematology
Hematopoietic Stem Cells
Humans
hydroxyurea
Hydroxyurea - administration & dosage
Hydroxyurea - pharmacology
JAK2V617F
Janus Kinase 2 - genetics
Medicine
Medicine & Public Health
Mutation, Missense
Oncology
Original Article
PhnegcMPD
Polycythemia Vera - blood
Polycythemia Vera - drug therapy
Polycythemia Vera - pathology
Thrombocythemia, Essential - blood
Thrombocythemia, Essential - drug therapy
Thrombocythemia, Essential - pathology
Thrombophilia - genetics
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ph-negative chronic myeloproliferative disorders (PhnegcMPD) are treated according to the estimated vascular risk. The recent discovery of V617F point mutation of the JAK2 kinase, which frequently occurs in these diseases, has not changed their management so far. However, emerging data tend to support a prothrombotic role for the mutation, along with a better response of JAK2V617F mutated patients to hydroxyurea treatment. Our data further support this notion.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-008-0650-1